Pulmonary Hypertension — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for pulmonary hypertension. 71 active patents protecting 3 drugs from 3+ originators. First major cliff: 2038. Daily refresh.

3
Approved drugs
71
Active US patents
63/100
Avg vulnerability
—
Annual revenue covered

Originators in Pulmonary Hypertension

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Vero Biotech Inc 66 patents Eli Lilly 4 patents AstraZeneca 1 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating pulmonary hypertension. Each bar = one year. Y-axis scaled to peak year (28 patents).

2
26
2
27
28
29
2
30
26
31
3
35
3
36
4
38
1
40

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Inomax
NITRIC OXIDE
 Vero Biotech Inc 66 67 — 2026-10-17
Cialis
tadalafil
 Eli Lilly 4 73 — 2038-12-24
Tracleer
BOSENTAN
 AstraZeneca 1 50 — 2027-12-28

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
11931377 Inomax method of use 81 2029-06-30
11931377 Inomax method of use 81 2029-06-30
7947227 Inomax method of use 80 2026-10-17
12186322 Cialis method of use 75 2038-12-24
11975006 Cialis method of use 75 2038-12-24
8795741 Inomax method of use 73 2029-06-30
8282966 Inomax method of use 73 2029-06-30
8282966 Inomax method of use 73 2029-06-30
8846112 Inomax method of use 73 2029-06-30
8431163 Inomax method of use 73 2029-06-30

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10213572 Inomax formulation 42 2036-02-12
10737051 Inomax formulation 42 2035-10-20
8607785 Inomax formulation 48 2030-07-14
11103669 Inomax formulation 48 2030-06-21
10926054 Inomax formulation 48 2029-08-13
8944049 Inomax formulation 48 2029-08-13
8573209 Inomax formulation 53 2031-01-06
8573209 Inomax formulation 53 2031-01-06
9701538 Inomax formulation 55 2029-01-28
7959945 Tracleer formulation 55 2027-12-28

Related